Abstract
In a retrospective cohort study of 68 organ transplant patients, the usefulness of a new commercial immunoglobulin A (IgA) antibody capture enzyme immunoassay (EIA) specific to human cytomegalovirus (CMV) for the early diagnosis of CMV disease was investigated. The results were compared with those obtained with the CMV pp65 antigen assay in peripheral blood leukocytes, an IgM immunoblot assay, and six other commercial ElAs. In 21 of 28 patients with CMV disease, the pp65 antigen assay and the immunoblot assay identified patients before the onset of disease more frequently than any other serological test method (17 and 13 patients, respectively; p=0.0029). In patients at risk for primary CMV infection, the pp65 antigen assay was the only method that identified all patients prior to the onset of CMV disease (p=0.008). For the other patients who were at risk for CMV infection, the pp65 antigen assay and the immunoblot assay detected infection before CMV disease more frequently than any other test system (p=0.026). With respect to CMV disease, both immunoblotting and the pp65 antigen assay showed excellent sensitivity (100% and 89%, respectively). However, the specificity of the immunoblot was poor (41%), while the specificity of the pp65 antigen assay was reasonably good (68%). The IgA capture EIA showed moderate sensitivity (61 %) and reasonable specificity (76%). In conclusion, the pp65 antigen assay, which detects pp65 antigen in leukocytes, is the method of choice for diagnosis of either primary or recurrent CMV infection. The specificity of the pp65 antigen assay was improved by additional testing for specific IgA and IgM antibodies (95% vs. 68%). The IgA assay is of limited value in renal and heart transplant patients, since it detected IgA antibodies only sporadically, and even then, too late for a timely therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Iberer T, Tscheliessnigg K, Halwachs G, Rehak R Wasler A, Petutschnigg B, Schreier G, Muller H, Allmayer T, Freigasser M, Prenner G, Hipmaier G, Grasser B: Definitions of cytomegalovirus disease after heart transplantation: antigenemia as a marker for antiviral therapy. Transplant International 1996, 9: 236–242.
Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA, and the City of Hope-Stanford-Syntex CMV study group: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogenic bone marrow transplants. New England Journal of Medicine 1991, 324: 1005–1011.
The TH, van den Berg AP, van Son WJ, Klompmarker IJ, Harmsen MC, van der Giessen M, Sloof MJH: Monitoring for cytomegalovirus after organ transplantation: a clinical perspective. Transplantation Proceedings 1993, 25, supplement 4: 4–9.
Bein G, Bitsch A, Hoyer J, Fricke L, Machnik H, Dennin R, Kirchner H: A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients. Transplant International 1993, 6: 185–190.
Mazulli T, Wood S, Chua R, Walmsley S: Evaluation of the digene hybrid capture system for the detection and quantification of human cytomegalovirus viremia in human immunodeficiency virus-infected patients. Journal of Clinical Microbiology 1996, 34: 2959–2962.
Veal N, Payan C, Fray D, Sarol L, Blanchet O, Kouyoumdjian S, Lunel F: Novel DNA assay for cytomegalovirus detection: comparison with conventional culture and pp65 antigenemia assay. Journal of Clinical Microbiology 1996, 34: 3097–3100.
van den Berg AP, van der Bij W, van Son WJ, Anema J, van der Giessen M, Schirm J, Tegzess AM, The TH: Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation — a report of 130 consecutive patients. Transplantation 1989, 48: 991–995.
van den Berg AP, van Son WJ, Jiwa NM, van der Bij W, Schirm J, van der Giessen M, The TH: Recent advances in the diagnosis of active cytomegalovirus infection after organ transplantation. Transplantation Proceedings 1990, 22: 226–228.
van den Berg AP, van Son WJ, Haagsma EB, Klompmaker IJ, Tegzess AM, Schirm J, Dijkstra G, van der Giessen M, Slooff MJ, The TH: Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. Transplantation 1993, 55: 847–851.
van der Bij W, Schirm J, Torensma R, van Son WJ, Tegzess AM, The TH: Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. Journal of Clinical Microbiology 1988, 26: 2531–2535.
van der Bij W, Torensma R, van Son WJ, Anema J, Schirm J, Tegzess AM, The TH: Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. Journal of Medical Virology 1988, 25: 179–188.
Braun W, Weber B, Moell U, Haman A, Doerr HW. Immunoglobulin A and M patterns to human cytomegalovirus during recurrent infection in patients with AIDS using a modified Western blot. Journal of Virological Methods 1993, 43: 65–76.
Engelhard D, Weinberg M, Or R, Shaked O, Naparstek E, Haikin H, Slavin S, Sarov I: Immunoglobulins A, G, and M to cytomegalovirus during recurrent infection of allogenic bone marrow transplantation. Journal of Infectious Diseases 1991, 163: 628–630.
Weber B, Braun W, Tyralla B, Doerr HW: Human cytomegalovirus (HCMV) specific IgE in primary HCMV infection. Clinical Investigation 1992, 70: 497–502.
Weber B, Hamann A, Ritt B, Rabenau H, Braun W, Doerr HW: Comparison of shell vial culture and serology for the diagnosis of human cytomegalovirus infection in neonates and immunocompromised subjects. Clinical Investigation 1992, 70: 503–507.
van Loon AM, Heessen FJA, van der Logt JTM: Antibody isotype response after human cytomegalovirus infection. Journal of Virological Methods 1987, 15: 101–107.
Pass RF, Griffiths PD, August AM: Antibody response to cytomegalovirus after renal transplantation: comparison of patients with primary and recurrent infections. Journal of Infectious Diseases 1983, 147: 40–46.
Fischer L, Rautenberg P, Bienengräber H, Leimenstoll G: Antigenemia, immunoblotting, and enzyme immunoassay for early diagnosis of cytomegalovirus infection in renal transplant patients. Transplant International 1993, 6: 201–205.
Rautenberg P, Meyer IC, Kaden J, Leimenstoll G, Engemann R: Temporal patterns of immunoblot reactive antibodies to cytomegalovirus in transplant recipients. Transplant International 1992, 5: 31–37.
Tukey, JW: Exploratory data analysis. Addison-Wesley, Reading, MA, 1977, p. 688.
Lutz E, Ward KN, Gray JJ: Maturation of antibody avidity after primary human cytomegalovirus infection is delayed in immunosuppressed solid organ transplant patients. Journal of Medical Virology 1994, 44: 317–322.
Nielsen SL, Sørensen I, Andersen HK: Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary, and secondary cytomegalovirus infection studied by antibody-capture enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 1988, 26: 654–661.
Sarov I, Friedman M, Levy E, Pascal L, Aymard M, Bosshard S, Chardonnet Y, Revillard JP: Detection of recurrent cytomegalovirus infection in renal transplant patients. Journal of Infectious Diseases 1984, 149: 277.
Grundy JE, Super M, Sweny P, Moorhead J, Lui SF, Berry NJ, Fernando ON, Griffiths PD: Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988, i: 132–135.
Chou S: Acquisition of donor strains of cytomegalovirus by renal transplant recipients. New England Journal of Medicine 1986, 314: 1418–1423.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rautenberg, P., Fischer, L., Tönnies, R. et al. Evaluation of a novel immunoglobulin a capture enzyme immunoassay for diagnosis of cytomegalovirus infection in renal and heart transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 16, 653–659 (1997). https://doi.org/10.1007/BF01708555
Issue Date:
DOI: https://doi.org/10.1007/BF01708555